Table 3 Change and change difference of accommodative amplitude and pupil diameter in three groups over 2-year.

From: Safety and efficacy of 0.02% and 0.01% atropine on controlling myopia progression: a 2-year clinical trial

Variables

Mean (95% CI)

0.02% atropine

0.01% atropine

Control group

Change difference between 0.02% and 0.01% atropine

0–4 months change

4–24 months change

0–24 months change

0–4 months change

4–24 months change

0–24 months change

0–24 months change

0–4 months

P value

4–24 months

P value

0–24 months

P value

Accommodative amplitude (diopters/month)

 − 0.71* (− 1.01 to − 0.41)

0.01 (− 0.01 to 0.03)

 − 0.11* (− 0.15 to − 0.06)

 − 0.57* (− 2.67 to − 1.95)

0.01 (− 0.02 to 0.04)

 − 0.09* (− 2.7 to − 0.1)

 − 0.03 (− 0.07 to 0.01)

 − 0.13 (− 0.32 to 0.06)

0.84

0 (− 0.02 to 0.02)

0.75

 − 0.02 (− 0.03 to 0.01)

0.69

Pupil diameter (mm/month)

0.24* (0.17 to 0.31)

0.002 (− 0.001 to 0.005)

0.04* (0.02 to 0.06)

0.24* (0.16 to 0.32)

0.001 (− 0.001 to 0.003)

0.04* (0.03 to 0.05)

0.001 (− 0.001 to 0.003)

0.001 (− 0.002 to 0.004)

0.89

0.001 (− 0.003 to 0.005)

0.91

0 (0 to 0.001)

0.76

  1. CI: confidence interval. Change: represents the slope of accommodative amplitude and pupil diameter over time for three groups.
  2. Change difference: represents the difference in slope of accommodative amplitude (D/month) and pupil diameter (mm/month) over time between each two groups.
  3. A generalized additive mixed model was used to estimate the longitudinal trend.
  4. *Represents: changes were significantly different.